RSV Vaccine

May 4, 2023

Today marks a turning point in our effort to reduce the significant burden of RSV. … Our focus now is to ensure eligible older adults in the US can access the vaccine as quickly as possible …

Chief Scientific Officer at GlaxoSmithKline (GSK), Tony Wood, on the Food and Drug Administration’s approval of GSK’s RSV vaccine for adults aged 60 years and older.

What is RSV? Respiratory syncytial virus is common and causes cold-like symptoms. While most people recover, it can be particularly serious for infants and older adults, causing more than 58,000 hospitalizations and around 300 deaths in children under 5 years old each year in the U.S.; it also causes 60,000 hospitalizations and over 6,000 deaths each year for older adults, according to the CDC.

Other pharmaceutical companies are also testing RSV vaccines; a vaccine developed by Pfizer for older adults could be approved by the end of May.

Why It Matters: This is the first time an RSV vaccine has ever been approved by a regulatory body worldwide, and offers adults aged 60 years and older a form of protection against the respiratory virus. The U.S launch of the vaccine is planned for before the 2023/2024 RSV season, which usually starts in the fall and peaks in the winter.

Also To Note: An RSV vaccine for infants (within first six months of life) is expected to be approved by the FDA later in 2023.

FDA approves GSK’s RSV vaccine for older adults, world’s first shot against virus (CNBC)

FDA approves first RSV vaccine, a long-sought scientific achievement (STAT)

US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults (GSK)

by Jenna Lee,